These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 29729144

  • 1. Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability.
    Padoan A, D'Incà R, Scapellato ML, De Bastiani R, Caccaro R, Mescoli C, Moz S, Bozzato D, Zambon CF, Lorenzon G, Rugge M, Plebani M, Basso D.
    Clin Chem Lab Med; 2018 Oct 25; 56(11):1926-1935. PubMed ID: 29729144
    [Abstract] [Full Text] [Related]

  • 2. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases.
    Buisson A, Mak WY, Andersen MJ, Lei D, Kahn SA, Pekow J, Cohen RD, Zmeter N, Pereira B, Rubin DT.
    J Crohns Colitis; 2019 Aug 14; 13(8):1012-1024. PubMed ID: 30726887
    [Abstract] [Full Text] [Related]

  • 3. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S, Boschetti G, Moussata D, Cotte E, Peyras J, Cuerq C, Haybrard J, Charlois AL, Mialon A, Chauvenet M, Stroeymeyt K, Kaiserlian D, Drai J, Flourié B.
    Inflamm Bowel Dis; 2013 Apr 14; 19(5):1043-52. PubMed ID: 23511035
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic Accuracy of Fecal Calprotectin for Pediatric Inflammatory Bowel Disease in Primary Care: A Prospective Cohort Study.
    Holtman GA, Lisman-van Leeuwen Y, Kollen BJ, Norbruis OF, Escher JC, Kindermann A, de Rijke YB, van Rheenen PF, Berger MY.
    Ann Fam Med; 2016 Sep 14; 14(5):437-45. PubMed ID: 27621160
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation.
    Mooiweer E, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B.
    Inflamm Bowel Dis; 2014 Feb 14; 20(2):307-14. PubMed ID: 24374878
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Fecal Calprotectin as a Useful Non-Invasive Screening Marker for Eosinophilic Gastrointestinal Disorder in Korean Children.
    Yoo IH, Cho JM, Joo JY, Yang HR.
    J Korean Med Sci; 2020 May 04; 35(17):e120. PubMed ID: 32356420
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
    Kotze LM, Nisihara RM, Marion SB, Cavassani MF, Kotze PG.
    Arq Gastroenterol; 2015 May 04; 52(1):50-4. PubMed ID: 26017083
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Reference Intervals for Fecal Calprotectin in Pregnant Women Using a Particle Enhanced Turbidimetric Assay.
    Fall T, Hedman A, Pershagen G, Andolf E, Almqvist C, Helmersson-Karlqvist J, Larsson A.
    Clin Lab; 2019 Jul 01; 65(7):. PubMed ID: 31307176
    [Abstract] [Full Text] [Related]

  • 18. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
    Mirsepasi-Lauridsen HC, Bachmann Holmetoft U, Ingdam Halkjær S, Angeliki Krogfelt K, Munk Petersen A.
    Scand J Gastroenterol; 2016 Jul 01; 51(2):211-7. PubMed ID: 26359672
    [Abstract] [Full Text] [Related]

  • 19. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity.
    Lee YW, Lee KM, Lee JM, Chung YY, Kim DB, Kim YJ, Chung WC, Paik CN.
    Korean J Intern Med; 2019 Jan 01; 34(1):72-80. PubMed ID: 29347813
    [Abstract] [Full Text] [Related]

  • 20. Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative Study.
    Zollner A, Schmiderer A, Reider SJ, Oberhuber G, Pfister A, Texler B, Watschinger C, Koch R, Effenberger M, Raine T, Tilg H, Moschen AR.
    J Crohns Colitis; 2021 Jan 13; 15(1):43-54. PubMed ID: 32556317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.